Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseBlue Cross Blue Shield - Maine RSV Prior Auth Cove…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MainePolicy N/A

    Prior authorization form and coverage criteria — RSV prophylaxis (palivizumab/Synagis)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Maine policy alerts

    Know when Blue Cross Blue Shield - Maine releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Provider-completed prior authorization form and clinical criteria for monoclonal antibody RSV prophylaxis (palivizumab/Synagis) with guidance on PA submission, documentation, and eligibility for Medicaid populations served by the payer.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyPrior authorization form and coverage criteria — RSV prophylaxis (palivizumab/Synagis)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the prior authorization form with full patient and clinical documentation; attest that Beyfortus was not received during the same RSV season.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    max 5approved Synagis doses per RSV season
    Nov 1–Mar 31defined RSV season

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <24 months
    age limit for eligibility
    fax providedPA fax lines

    Coverage Criteria for RSV Prophylaxis (palivizumab / Synagis)

    Initial Synagis eligibility

    Approved for a maximum of five doses when ANY of the following high-risk conditions are met for patients meeting age/weight criteria

    Synagis approval criteria

    • Prematurity - very preterm: Member was born before 29 weeks 0 days' gestation.
    • Prematurity with chronic lung disease: Member was born before 32 weeks 0 days' gestation AND has chronic lung disease necessitating >21% oxygen for at least the first 28 days of life (provide dates of oxygen supplementation/medication intervention).
    • Hemodynamically significant heart disease: Member has hemodynamically significant heart disease (for example, acyanotic heart disease receiving medication to control congestive heart failure and will require cardiac surgical procedures, or moderate to severe pulmonary hypertension). Provide relevant diagnoses/medical intervention.
    • Congenital airway or neuromuscular disease: Member has a congenital airway abnormality or neuromuscular disease that impairs the ability to clear secretions. Provide relevant diagnoses/medication intervention.
    • Cystic fibrosis with clinical compromise: Member has cystic fibrosis with clinical evidence of chronic lung disease and/or nutritional compromise.
    • Profound immunocompromise: Member is or will be considered to be profoundly immunocompromised during the RSV season (must provide chart documentation and explicitly state how member is or will be profoundly immunocompromised), including members undergoing cardiac transplantation during the current RSV season. Please explain and provide documentation.
    Age and dosing limits: Current age must be < 24 months. Dosage: palivizumab 15 mg/kg IM once per month through March 31st (maximum of five doses per RSV season).maximum five doses per season

    Second-season Synagis eligibility

    For members approaching a second RSV season or older infants, additional criteria may be required

    Second season / continued therapy

    • Prematurity with ongoing respiratory support: Member was born before 32 weeks 0 days' gestation, required at least 28 days of supplemental oxygen after birth, and continued to require supplemental oxygen, chronic systemic corticosteroid therapy, diuretic, or bronchodilator therapy within 6 months of the start of the second RSV season. Provide dates of oxygen supplementation/medication intervention.
    • Cystic fibrosis with severe disease or poor growth: Member has cystic fibrosis with manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or persistent abnormalities on chest imaging when stable) OR weight-for-length < 10th percentile. Provide relevant diagnoses/medical intervention.

    Prescriber must attest that the member has not received Beyfortus (nirsevimab) within the same RSV season. Prior receipt of Beyfortus during the season excludes coverage of Synagis (palivizumab) for that season until the prescriber provides the required attestation on the PA form. The PA form includes a prescriber signature line to confirm this attestation.

    Key Clinical Coding & Eligibility Definitions

    inv-04: Current age
    Required age for initial eligibilityMust be less than 24 months at time of request
    Field on PA formCurrent age documented in months on PA form (Current age (Must be < 24 months): __months)
    Applies toInitial Synagis (palivizumab) prophylaxis requests
    inv-05: Gestational age
    Primary gestational thresholdBorn before 29 weeks, 0 days' gestation (qualifies if <12 months of age)
    Alternate gestational threshold with additional criteriaBorn before 32 weeks, 0 days' gestation AND has chronic lung disease requiring >21% oxygen for at least the first 28 days of life (or for second-season eligibility: born before 32 weeks and required ≥28 days supplemental oxygen after birth plus ongoing respiratory therapy within 6 months of second season)

    Provider Requirements and Prior Authorization Process

    Prior Authorization

    Submit PA form via fax to Prior Authorization of Benefits Center

    Complete and fax the provider-completed PA form to the Prior Authorization of Benefits Center at 844-864-7860 for retail services or 888-209-7838 for medical injectable services to request prior authorization.

    Step Therapy

    Provide medical justification and attestation for Synagis over Beyfortus

    If requesting palivizumab (Synagis) instead of Beyfortus (nirsevimab), the prescriber must submit valid medical justification on the PA form and attest whether Beyfortus has not been received in the same RSV season.

    • Include written medical justification in the designated section of the form (item 4).
    • Sign the attestation that the member has not received Beyfortus in the same RSV season (item 5).

    Background

    This PA form supports prophylactic use of monoclonal antibodies for respiratory syncytial virus (RSV) in high‑risk infants and young children. It documents clinical eligibility elements (for example, prematurity with specific gestational-age thresholds and oxygen/medication requirements, cystic fibrosis with severe lung disease, and other high‑risk conditions), requires prescriber justification when requesting Synagis over Beyfortus, and limits prophylaxis to a maximum of five doses or until the end of the RSV season, whichever comes first. The form also defines the RSV season as November 1 through March 31 and notes the Office of Medicaid Policy & Planning may extend the season based on statewide virology data.

    Operational Definitions

    inv-11: RSV season
    Season start and endDefined as November 1 through March 31
    Possible extensionOffice of Medicaid Policy & Planning may extend the season based on statewide virology data
    Impact on dosingRequests for additional doses beyond the season or initial five doses require separate prior authorization
    inv-12: Maximum doses
    Maximum doses per seasonProphylaxis limited to a maximum of five doses per RSV season
    Alternate stopping ruleProphylaxis given only until the infant/child reaches five doses OR the end of the RSV season, whichever comes first
    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyPrior authorization form and coverage criteria — RSV prophylaxis (palivizumab/Synagis)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the prior authorization form with full patient and clinical documentation; attest that Beyfortus was not received during the same RSV season.
    SourceLink
    On This Page
    Coverage Criteria for RSV Prophylaxis (palivizumab / Synagis)Key Clinical Coding & Eligibility DefinitionsProvider Requirements and Prior Authorization ProcessBackgroundOperational Definitions
    Documentation requiredProvide actual gestational age (weeks/days) and dates of oxygen supplementation/medication interventions on PA form
    Documentation Required

    Complete required PA form fields and supporting clinical documentation

    Complete the PA form fields requested: patient identifiers, prescriber information, requested medication and dosing, and clinical details relevant to eligibility; include the medical justification section when requesting Synagis over Beyfortus and the prescriber attestation regarding prior Beyfortus receipt.

    • Patient: Medicaid number, date of birth, patient name.
    • Prescriber: name, Indiana license number, specialty, NPI, signature and return contact info.
    • Medication: requested medication name, strength, dosage regimen.
    • Clinical details: gestational age, current age and weight, dates of oxygen supplementation/medication interventions, diagnoses/interventions, and chart documentation for profound immunocompromise if applicable.
    • If applicable, include medical justification for Synagis over Beyfortus and the attestation that Beyfortus was not received this RSV season.
    Denial Risk

    Ensure the PA form is fully completed or request will be returned

    All sections of the PA form must be completed; incomplete or partially completed forms will be returned and the request will not be processed.

    • The form must be completed by the prescribing provider and include the required prescriber signature in the attestation section.
    • Mark the retroactive PA box and provide dates of service when applicable; submit retroactive requests separately per form instructions.
    Additional doses
    Requests for doses beyond the initial five approved doses require separate prior authorization